RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder. BTCs are aggressive tumors with limited treatment options and poor overall survival. Currently, surgery remains to be the only potentially curative treatment, and most patients develop recurrence. For advanced tumors, only limited effective treatment modalities exist today. Gemcitabine plus cisplatin is considered as a standard option for advanced biliary cancer. A randomized phase III trial (ABC-02 trial) showed superiority of gemcitabine plus cisplatin over gemcitabine alone. In that study, they showed that after a median follow-up of 8.2 months, the median overall survival was 8.1 months in the gemcitabine-only group and 11.7 months in the gemcitabine plus cisplatin group (p<0.001). However, while this is a definite advancement, a 3-month survival extension among patients with BTC is modest at best. Moreover, this regimen has not been compared head-to-head with other gemcitabine based combinations. Gemcitabine monotherapy, 5-fluorouracil plus leucovorin, and single- agent capecitabine are all reasonable options for patients with a borderline performance status. Recent advancements have provided new insight into the genomic landscape of BTCs, and thus, it remains unclear whether combined treatment with molecular targeted agents or other cytotoxic chemotherapeutic agents may also be effective against advanced BTC. (Korean J Gastroenterol 2017;69:172-176)

번역하기

참고문헌 (Reference)

1 Chen JS, "Weekly 24h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas" 9 : 393-397, 1998

2 Howell M, "The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma" 29 : 333-343, 2015

3 Burris H MI, "The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas" 14 (14): PL04-PL05, 2015

4 Bang YJ, "Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028" 51 (51): S112-, 2015

5 Lubner SJ, "Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study" 28 : 3491-3497, 2010

6 Malik IA, "Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder" 26 : 124-126, 2003

7 Park I, "Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy" 115 : 4148-4155, 2009

8 Park SH, "Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma" 106 : 361-365, 2006

9 Kim TW, "Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer" 14 : 1115-1120, 2003

10 Hong YS, "Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer" 60 : 321-328, 2007